nach oben

Cancer and Metastasis Reviews

Erschienen in:

25.01.2023

The role of cancer cell bioenergetics in dormancy and drug resistance

verfasst von: Steven Tau, Todd W. Miller

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Abstract

While anti-cancer drug treatments are often effective for the clinical management of cancer, these treatments frequently leave behind drug-tolerant persister cancer cells that can ultimately give rise to recurrent disease. Such persistent cancer cells can lie dormant for extended periods of time, going undetected by conventional clinical means. Understanding the mechanisms that such dormant cancer cells use to survive, and the mechanisms that drive emergence from dormancy, is critical to the development of improved therapeutic strategies to prevent and manage disease recurrence. Cancer cells often exhibit metabolic alterations compared to their non-transformed counterparts. An emerging body of evidence supports the notion that dormant cancer cells also have unique metabolic adaptations that may offer therapeutically targetable vulnerabilities. Herein, we review mechanisms through which cancer cells metabolically adapt to persist during drug treatments and develop drug resistance. We also highlight emerging therapeutic strategies to target dormant cancer cells via their metabolic features.

Vallette, F. M., Olivier, C., Lézot, F., Oliver, L., Cochonneau, D., Lalier, L., Cartron, P.-F., & Heymann, D. (2019). Dormant, quiescent, tolerant and persister cells: Four synonyms for the same target in cancer. Biochemical Pharmacology, 162, 169–176. https://doi.org/10.1016/j.bcp.2018.11.004CrossRefPubMed

Aguirre-Ghiso, J. A. (2007). Models, mechanisms and clinical evidence for cancer dormancy. Nature Reviews Cancer, 7(11), 834–846. https://doi.org/10.1038/nrc2256CrossRefPubMedPubMedCentral

Sosa, M. S., Bragado, P., & Aguirre-Ghiso, J. A. (2014). Mechanisms of disseminated cancer cell dormancy: an awakening field. Nature Reviews Cancer, 14(9), 611–622. https://doi.org/10.1038/nrc3793CrossRefPubMedPubMedCentral

Roesch, A., Vultur, A., Bogeski, I., Wang, H., Zimmermann, K. M., Speicher, D., Körbel, C., Laschke, M. W., Gimotty, P. A., Philipp, S. E., et al. (2013). Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. Cancer Cell, 23(6), 811–825. https://doi.org/10.1016/j.ccr.2013.05.003CrossRefPubMed

Jin, X., Demere, Z., Nair, K., Ali, A., Ferraro, G. B., Natoli, T., Deik, A., Petronio, L., Tang, A. A., Zhu, C., et al. (2020). A metastasis map of human cancer cell lines. Nature, 588(7837), 331–336. https://doi.org/10.1038/s41586-020-2969-2CrossRefPubMedPubMedCentral

Ward, P. S., & Thompson, C. B. (2012). Metabolic reprogramming: A cancer hallmark even warburg did not anticipate. Cancer Cell, 21(3), 297–308. https://doi.org/10.1016/j.ccr.2012.02.014CrossRefPubMedPubMedCentral

DeBerardinis, R. J., Lum, J. J., Hatzivassiliou, G., & Thompson, C. B. (2008). The biology of cancer: Metabolic reprogramming fuels cell growth and proliferation. Cell Metabolism, 7(1), 11–20. https://doi.org/10.1016/j.cmet.2007.10.002CrossRefPubMed

DeNicola, G. M., & Cantley, L. C. (2015). Cancer’s fuel choice: New flavors for a picky eater. Molecular cell, 60(4), 514–523. https://doi.org/10.1016/j.molcel.2015.10.018CrossRefPubMedPubMedCentral

Reinfeld, B. I., Madden, M. Z., Wolf, M. M., Chytil, A., Bader, J. E., Patterson, A. R., Sugiura, A., Cohen, A. S., Ali, A., Do, B. T., et al. (2021). Cell-programmed nutrient partitioning in the tumour microenvironment. Nature, 593(7858), 282–288. https://doi.org/10.1038/s41586-021-03442-1CrossRefPubMedPubMedCentral

10.

Lum, J. J., Bauer, D. E., Kong, M., Harris, M. H., Li, C., Lindsten, T., & Thompson, C. B. (2005). Growth factor regulation of autophagy and cell survival in the absence of apoptosis. Cell, 120(2), 237–248. https://doi.org/10.1016/j.cell.2004.11.046CrossRefPubMed

11.

Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009). Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science, 324(5930), 1029–1033. https://doi.org/10.1126/science.1160809CrossRefPubMedPubMedCentral

12.

Endo, H., Okuyama, H., Ohue, M., & Inoue, M. (2014). Dormancy of cancer cells with suppression of AKT activity contributes to survival in chronic hypoxia. PLOS ONE, 9(6), e98858. https://doi.org/10.1371/journal.pone.0098858CrossRefPubMedPubMedCentral

13.

Assaily, W., Rubinger, D. A., Wheaton, K., Lin, Y., Ma, W., Xuan, W., Brown-Endres, L., Tsuchihara, K., Mak, T. W., & Benchimol, S. (2011). ROS-mediated p53 induction of Lpin1 regulates fatty acid oxidation in response to nutritional stress. Molecular Cell, 44(3), 491–501. https://doi.org/10.1016/j.molcel.2011.08.038CrossRefPubMed

14.

Zaugg, K., Yao, Y., Reilly, P. T., Kannan, K., Kiarash, R., Mason, J., Huang, P., Sawyer, S. K., Fuerth, B., Faubert, B., et al. (2011). Carnitine palmitoyltransferase 1C promotes cell survival and tumor growth under conditions of metabolic stress. Genes & Development, 25(10), 1041–1051. https://doi.org/10.1101/gad.1987211CrossRef

15.

Wang, C., Li, Z., Lu, Y., Du, R., Katiyar, S., Yang, J., Fu, M., Leader, J. E., Quong, A., Novikoff, P. M., et al. (2006). Cyclin D1 repression of nuclear respiratory factor 1 integrates nuclear DNA synthesis and mitochondrial function. Proceedings of the National Academy of Sciences, 103(31), 11567–11572. https://doi.org/10.1073/pnas.0603363103CrossRef

16.

Lopez-Mejia, I. C., Lagarrigue, S., Giralt, A., Martinez-Carreres, L., Zanou, N., Denechaud, P.-D., Castillo-Armengol, J., Chavey, C., Orpinell, M., Delacuisine, B., et al. (2017). CDK4 phosphorylates AMPKα2 to inhibit its activity and repress fatty acid oxidation. Molecular Cell, 68(2), 336–349.e6. https://doi.org/10.1016/j.molcel.2017.09.034CrossRefPubMed

17.

Toyama, E. Q., Herzig, S., Courchet, J., Lewis, T. L., Losón, O. C., Hellberg, K., Young, N. P., Chen, H., Polleux, F., Chan, D. C., et al. (2016). AMP-activated protein kinase mediates mitochondrial fission in response to energy stress. Science, 351(6270), 275–281. https://doi.org/10.1126/science.aab4138CrossRefPubMedPubMedCentral

18.

Camarda, R., Zhou, A. Y., Kohnz, R. A., Balakrishnan, S., Mahieu, C., Anderton, B., Eyob, H., Kajimura, S., Tward, A., Krings, G., et al. (2016). Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer. Nature Medicine, 22(4), 427–432. https://doi.org/10.1038/nm.4055CrossRefPubMedPubMedCentral

19.

Madak-Erdogan, Z., Band, S., Zhao, Y. C., Smith, B. P., Kulkoyluoglu-Cotul, E., Zuo, Q., Santaliz Casiano, A., Wrobel, K., Rossi, G., Smith, R. L., et al. (2019). Free fatty acids rewire cancer metabolism in obesity-associated breast cancer via estrogen receptor and mTOR signaling. Cancer Research, canres.2849.2018. https://doi.org/10.1158/0008-5472.CAN-18-2849

20.

Havas, K. M., Milchevskaya, V., Radic, K., Alladin, A., Kafkia, E., Garcia, M., Stolte, J., Klaus, B., Rotmensz, N., Gibson, T. J., et al. (2017). Metabolic shifts in residual breast cancer drive tumor recurrence. Journal of Clinical Investigation, 127(6), 2091–2105. https://doi.org/10.1172/JCI89914CrossRefPubMedPubMedCentral

21.

Fox, D. B., Garcia, N. M. G., McKinney, B. J., Lupo, R., Noteware, L. C., Newcomb, R., Liu, J., Locasale, J. W., Hirschey, M. D., & Alvarez, J. V. (2020). NRF2 activation promotes the recurrence of dormant tumour cells through regulation of redox and nucleotide metabolism. Nature Metabolism, 2(4), 318–334. https://doi.org/10.1038/s42255-020-0191-zCrossRefPubMedPubMedCentral

22.

Shen, S., Faouzi, S., Souquere, S., Roy, S., Routier, E., Libenciuc, C., André, F., Pierron, G., Scoazec, J.-Y., & Robert, C. (2020). Melanoma persister cells are tolerant to BRAF/MEK inhibitors via ACOX1-mediated fatty acid oxidation. Cell Reports, 33(8), 108421. https://doi.org/10.1016/j.celrep.2020.108421CrossRefPubMed

23.

Hampsch, R. A., Wells, J. D., Traphagen, N. A., McCleery, C. F., Fields, J. L., Shee, K., Dillon, L. M., Pooler, D. B., Lewis, L. D., Demidenko, E., et al. (2020). ampk activation by metformin promotes survival of dormant ER + breast cancer cells. Clinical Cancer Research, 26(14), 3707–3719. https://doi.org/10.1158/1078-0432.CCR-20-0269CrossRefPubMedPubMedCentral

24.

Luo, Z., Zang, M., & Guo, W. (2010). AMPK as a metabolic tumor suppressor: control of metabolism and cell growth. Future Oncology, 6(3), 457–470. https://doi.org/10.2217/fon.09.174CrossRefPubMed

25.

Li, Y., Liang, R., Sun, M., Li, Z., Sheng, H., Wang, J., Xu, P., Liu, S., Yang, W., Lu, B., et al. (2020). AMPK-dependent phosphorylation of HDAC8 triggers PGM1 expression to promote lung cancer cell survival under glucose starvation. Cancer Letters, 478, 82–92. https://doi.org/10.1016/j.canlet.2020.03.007CrossRefPubMed

26.

Naik, P. P., Mukhopadhyay, S., Praharaj, P. P., Bhol, C. S., Panigrahi, D. P., Mahapatra, K. K., Patra, S., Saha, S., Panda, A. K., Panda, K., et al. (2021). Secretory clusterin promotes oral cancer cell survival via inhibiting apoptosis by activation of autophagy in AMPK/mTOR/ULK1 dependent pathway. Life Sciences, 264, 118722. https://doi.org/10.1016/j.lfs.2020.118722CrossRefPubMed

27.

Ferretti, A. C., Tonucci, F. M., Hidalgo, F., Almada, E., Larocca, M. C., & Favre, C. (2016). AMPK and PKA interaction in the regulation of survival of liver cancer cells subjected to glucose starvation. Oncotarget, 7(14), 17815–17828. https://doi.org/10.18632/oncotarget.7404CrossRefPubMedPubMedCentral

28.

Chaube, B., Malvi, P., Singh, S. V., Mohammad, N., Viollet, B., & Bhat, M. K. (2015). AMPK maintains energy homeostasis and survival in cancer cells via regulating p38/PGC-1α-mediated mitochondrial biogenesis. Cell Death Discovery, 1(1), 1–11. https://doi.org/10.1038/cddiscovery.2015.63CrossRef

29.

Peart, T., Valdes, Y. R., Correa, R. J. M., Fazio, E., Bertrand, M., McGee, J., Préfontaine, M., Sugimoto, A., DiMattia, G. E., & Shepherd, T. G. (2015). Intact LKB1 activity is required for survival of dormant ovarian cancer spheroids. Oncotarget, 6(26), 22424–22438.CrossRefPubMedPubMedCentral

30.

You, B., Xia, T., Gu, M., Zhang, Z., Zhang, Q., Shen, J., Fan, Y., Yao, H., Pan, S., Lu, Y., et al. (2022). AMPK–mTOR–mediated activation of autophagy promotes formation of dormant polyploid giant cancer cells. Cancer Research, 82(5), 846–858. https://doi.org/10.1158/0008-5472.CAN-21-2342CrossRefPubMedPubMedCentral

31.

Lu, Z., Luo, R. Z., Lu, Y., Zhang, X., Yu, Q., Khare, S., Kondo, S., Kondo, Y., Yu, Y., Mills, G. B., et al. (2008). The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells. The Journal of Clinical Investigation, 118(12), 3917–3929. https://doi.org/10.1172/JCI35512CrossRefPubMedPubMedCentral

32.

Kim, S. M., Nguyen, T. T., Ravi, A., Kubiniok, P., Finicle, B. T., Jayashankar, V., Malacrida, L., Hou, J., Robertson, J., Gao, D., et al. (2018). PTEN deficiency and AMPK activation promote nutrient scavenging and anabolism in prostate cancer cells. Cancer Discovery, 8(7), 866–883. https://doi.org/10.1158/2159-8290.CD-17-1215CrossRefPubMedPubMedCentral

33.

Glatz, J. F. C., & Luiken, J. J. F. P. (2020). Time for a détente in the war on the mechanism of cellular fatty acid uptake. Journal of Lipid Research, 61(9), 1300–1303. https://doi.org/10.1194/jlr.6192020LTECrossRefPubMedPubMedCentral

34.

Ladanyi, A., Mukherjee, A., Kenny, H. A., Johnson, A., Mitra, A. K., Sundaresan, S., Nieman, K. M., Pascual, G., Benitah, S. A., Montag, A., et al. (2018). Adipocyte-induced CD36 expression drives ovarian cancer progression and metastasis. Oncogene, 37(17), 2285–2301. https://doi.org/10.1038/s41388-017-0093-zCrossRefPubMedPubMedCentral

35.

Zhao, J., Zhi, Z., Wang, C., Xing, H., Song, G., Yu, X., Zhu, Y., Wang, X., Zhang, X., & Di, Y. (2017). Exogenous lipids promote the growth of breast cancer cells via CD36. Oncology Reports, 38(4), 2105–2115. https://doi.org/10.3892/or.2017.5864CrossRefPubMedPubMedCentral

36.

Drury, J., Rychahou, P. G., He, D., Jafari, N., Wang, C., Lee, E. Y., Weiss, H. L., Evers, B. M., & Zaytseva, Y. Y. (2020). Inhibition of fatty acid synthase upregulates expression of cd36 to sustain proliferation of colorectal cancer cells. Frontiers in Oncology, 10 Retrieved from https://www.frontiersin.org/article/10.3389/fonc.2020.01185

37.

Farge, T., Saland, E., de Toni, F., Aroua, N., Hosseini, M., Perry, R., Bosc, C., Sugita, M., Stuani, L., Fraisse, M., et al. (2017). Chemotherapy-resistant human acute myeloid leukemia cells are not enriched for leukemic stem cells but require oxidative metabolism. Cancer Discovery, 7(7), 716–735. https://doi.org/10.1158/2159-8290.CD-16-0441CrossRefPubMedPubMedCentral

38.

Pascual, G., Avgustinova, A., Mejetta, S., Martín, M., Castellanos, A., Attolini, C. S.-O., Berenguer, A., Prats, N., Toll, A., Hueto, J. A., et al. (2017). Targeting metastasis-initiating cells through the fatty acid receptor CD36. Nature, 541(7635), 41–45. https://doi.org/10.1038/nature20791CrossRefPubMed

39.

Landberg, N., von Palffy, S., Askmyr, M., Lilljebjörn, H., Sandén, C., Rissler, M., Mustjoki, S., Hjorth-Hansen, H., Richter, J., Ågerstam, H., et al. (2018). CD36 defines primitive chronic myeloid leukemia cells less responsive to imatinib but vulnerable to antibody-based therapeutic targeting. Haematologica, 103(3), 447–455. https://doi.org/10.3324/haematol.2017.169946CrossRefPubMedPubMedCentral

40.

Aloia, A., Müllhaupt, D., Chabbert, C. D., Eberhart, T., Flückiger-Mangual, S., Vukolic, A., Eichhoff, O., Irmisch, A., Alexander, L. T., Scibona, E., et al. (2019). A fatty acid oxidation-dependent metabolic shift regulates the adaptation of BRAF-mutated melanoma to MAPK inhibitors. Clinical Cancer Research, 25(22), 6852–6867. https://doi.org/10.1158/1078-0432.CCR-19-0253CrossRefPubMedPubMedCentral

41.

Park, J. H., Vithayathil, S., Kumar, S., Sung, P.-L., Dobrolecki, L. E., Putluri, V., Bhat, V. B., Bhowmik, S. K., Gupta, V., Arora, K., et al. (2016). Fatty acid oxidation-driven Src links mitochondrial energy reprogramming and oncogenic properties in triple-negative breast cancer. Cell Reports, 14(9), 2154–2165. https://doi.org/10.1016/j.celrep.2016.02.004CrossRefPubMed

42.

Liang, H., & Ward, W. F. (2006). PGC-1alpha: A key regulator of energy metabolism. Advances in Physiology Education, 30(4), 145–151. https://doi.org/10.1152/advan.00052.2006CrossRefPubMed

43.

Ying, H., Kimmelman, A. C., Lyssiotis, C. A., Hua, S., Chu, G. C., Fletcher-Sananikone, E., Locasale, J. W., Son, J., Zhang, H., Coloff, J. L., et al. (2012). Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell, 149(3), 656–670. https://doi.org/10.1016/j.cell.2012.01.058CrossRefPubMedPubMedCentral

44.

Bosc, C., Saland, E., Bousard, A., Gadaud, N., Sabatier, M., Cognet, G., Farge, T., Boet, E., Gotanègre, M., Aroua, N., et al. (2021). Mitochondrial inhibitors circumvent adaptive resistance to venetoclax and cytarabine combination therapy in acute myeloid leukemia. Nature Cancer, 2(11), 1204–1223. https://doi.org/10.1038/s43018-021-00264-yCrossRefPubMed

45.

Henkenius, K., Greene, B. H., Barckhausen, C., Hartmann, R., Märken, M., Kaiser, T., Rehberger, M., Metzelder, S. K., Parak, W. J., Neubauer, A., et al. (2017). Maintenance of cellular respiration indicates drug resistance in acute myeloid leukemia. Leukemia Research, 62, 56–63. https://doi.org/10.1016/j.leukres.2017.09.021CrossRefPubMed

46.

Echeverria, G. V., Ge, Z., Seth, S., Zhang, X., Jeter-Jones, S., Zhou, X., Cai, S., Tu, Y., McCoy, A., Peoples, M., et al. (2019). Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state. Science Translational Medicine, 11(488), 936. https://doi.org/10.1126/scitranslmed.aav0936CrossRef

47.

Lee, K., Giltnane, J. M., Balko, J. M., Schwarz, L. J., Guerrero-Zotano, A. L., Hutchinson, K. E., Nixon, M. J., Estrada, M. V., Sánchez, V., Sanders, M. E., et al. (2017). MYC and MCL1 cooperatively promote chemotherapy-resistant breast cancer stem cells via regulation of mitochondrial oxidative phosphorylation. Cell Metabolism, 26(4), 633–647.e7. https://doi.org/10.1016/j.cmet.2017.09.009CrossRefPubMedPubMedCentral

48.

Buschhaus, J. M., Humphries, B. A., Eckley, S. S., Robison, T. H., Cutter, A. C., Rajendran, S., Haley, H. R., Bevoor, A. S., Luker, K. E., & Luker, G. D. (2020). Targeting disseminated estrogen-receptor-positive breast cancer cells in bone marrow. Oncogene, 39(34), 5649–5662. https://doi.org/10.1038/s41388-020-01391-zCrossRefPubMedPubMedCentral

49.

Franco, J., Balaji, U., Freinkman, E., Witkiewicz, A. K., & Knudsen, E. S. (2016). Metabolic reprogramming of pancreatic cancer mediated by CDK4/6 inhibition elicits unique vulnerabilities. Cell Reports, 14(5), 979–990. https://doi.org/10.1016/j.celrep.2015.12.094CrossRefPubMed

50.

Kunimasa, K., Nagano, T., Shimono, Y., Dokuni, R., Kiriu, T., Tokunaga, S., Tamura, D., Yamamoto, M., Tachihara, M., Kobayashi, K., et al. (2017). Glucose metabolism-targeted therapy and withaferin A are effective for epidermal growth factor receptor tyrosine kinase inhibitor-induced drug-tolerant persisters. Cancer Science, 108(7), 1368–1377. https://doi.org/10.1111/cas.13266CrossRefPubMedPubMedCentral

51.

Dörr, J. R., Yu, Y., Milanovic, M., Beuster, G., Zasada, C., Däbritz, J. H. M., Lisec, J., Lenze, D., Gerhardt, A., Schleicher, K., et al. (2013). Synthetic lethal metabolic targeting of cellular senescence in cancer therapy. Nature, 501(7467), 421–425. https://doi.org/10.1038/nature12437CrossRefPubMed

52.

Goldman, A., Khiste, S., Freinkman, E., Dhawan, A., Majumder, B., Mondal, J., Pinkerton, A. B., Eton, E., Medhi, R., Chandrasekar, V., et al. (2019). Targeting tumor phenotypic plasticity and metabolic remodeling in adaptive cross-drug tolerance. Science Signaling, 12(595), eaas8779. https://doi.org/10.1126/scisignal.aas8779CrossRefPubMedPubMedCentral

53.

Zhang, W. C., Wells, J. M., Chow, K.-H., Huang, H., Yuan, M., Saxena, T., Melnick, M. A., Politi, K., Asara, J. M., Costa, D. B., et al. (2019). miR-147b-mediated TCA cycle dysfunction and pseudohypoxia initiate drug tolerance to EGFR inhibitors in lung adenocarcinoma. Nature Metabolism, 1(4), 460–474. https://doi.org/10.1038/s42255-019-0052-9CrossRefPubMedPubMedCentral

54.

Patel, S. B., Nemkov, T., Stefanoni, D., Benavides, G. A., Bassal, M. A., Crown, B. L., Matkins, V. R., Camacho, V., Kuznetsova, V., Hoang, A. T., et al. (2021). Metabolic alterations mediated by STAT3 promotes drug persistence in CML. Leukemia, 35(12), 3371–3382. https://doi.org/10.1038/s41375-021-01315-0CrossRefPubMedPubMedCentral

55.

Paredes, F., Williams, H. C., & San Martin, A. (2021). Metabolic adaptation in hypoxia and cancer. Cancer Letters, 502, 133–142. https://doi.org/10.1016/j.canlet.2020.12.020CrossRefPubMedPubMedCentral

56.

Harper, M.-E., Antoniou, A., Villalobos-Menuey, E., Russo, A., Trauger, R., Vendemelio, M., George, A., Bartholomew, R., Carlo, D., Shaikh, A., et al. (2002). Characterization of a novel metabolic strategy used by drug-resistant tumor cells. The FASEB Journal, 16(12), 1550–1557. https://doi.org/10.1096/fj.02-0541comCrossRefPubMed

57.

Oren, Y., Tsabar, M., Cuoco, M. S., Amir-Zilberstein, L., Cabanos, H. F., Hütter, J.-C., Hu, B., Thakore, P. I., Tabaka, M., Fulco, C. P., et al. (2021). Cycling cancer persister cells arise from lineages with distinct programs. Nature, 1–7. https://doi.org/10.1038/s41586-021-03796-6

58.

Pike, L. S., Smift, A. L., Croteau, N. J., Ferrick, D. A., & Wu, M. (2011). Inhibition of fatty acid oxidation by etomoxir impairs NADPH production and increases reactive oxygen species resulting in ATP depletion and cell death in human glioblastoma cells. Biochimica et Biophysica Acta (BBA). Bioenergetics, 1807(6), 726–734. https://doi.org/10.1016/j.bbabio.2010.10.022CrossRef

59.

Jeon, S.-M., Chandel, N. S., & Hay, N. (2012). AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. Nature, 485(7400), 661–665. https://doi.org/10.1038/nature11066CrossRefPubMedPubMedCentral

60.

Kaplan, O., Navon, G., Lyon, R. C., Faustino, P. J., Straka, E. J., & Cohen, J. S. (1990). Effects of 2-deoxyglucose on drug-sensitive and drug-resistant human breast cancer cells: Toxicity and magnetic resonance spectroscopy studies of metabolism. Cancer Research, 50(3), 544–551.PubMed

61.

La Belle Flynn, A., Calhoun, B. C., Sharma, A., Chang, J. C., Almasan, A., & Schiemann, W. P. (2019). Autophagy inhibition elicits emergence from metastatic dormancy by inducing and stabilizing Pfkfb3 expression. Nature Communications, 10(1), 3668. https://doi.org/10.1038/s41467-019-11640-9CrossRefPubMedPubMedCentral

62.

Morris, V. L., Tuck, A. B., Wilson, S. M., Percy, D., & Chambers, A. F. (1993). Tumor progression and metastasis in murine D2 hyperplastic alveolar nodule mammary tumor cell lines. Clinical & Experimental Metastasis, 11(1), 103–112. https://doi.org/10.1007/BF00880071CrossRef

63.

Rusu, P., Shao, C., Neuerburg, A., Acikgöz, A. A., Wu, Y., Zou, P., Phapale, P., Shankar, T. S., Döring, K., Dettling, S., et al. (2019). GPD1 specifically marks dormant glioma stem cells with a distinct metabolic profile. Cell Stem Cell, 25(2), 241–257.e8. https://doi.org/10.1016/j.stem.2019.06.004CrossRefPubMed

64.

Chino, H. (1957). Conversion of glycogen to sorbitol and glycerol in the diapause egg of the bombyx silkworm. Nature, 180(4586), 606–607. https://doi.org/10.1038/180606b0CrossRef

65.

Vyas, S., Zaganjor, E., & Haigis, M. C. (2016). Mitochondria and cancer. Cell, 166(3), 555–566. https://doi.org/10.1016/j.cell.2016.07.002CrossRefPubMedPubMedCentral

66.

Viale, A., Pettazzoni, P., Lyssiotis, C. A., Ying, H., Sánchez, N., Marchesini, M., Carugo, A., Green, T., Seth, S., Giuliani, V., et al. (2014). Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature, 514(7524), 628–632. https://doi.org/10.1038/nature13611CrossRefPubMedPubMedCentral

67.

Samuels, A. L., Heng, J. Y., Beesley, A. H., & Kees, U. R. (2014). Bioenergetic modulation overcomes glucocorticoid resistance in T-lineage acute lymphoblastic leukaemia. British Journal of Haematology, 165(1), 57–66. https://doi.org/10.1111/bjh.12727CrossRefPubMed

68.

Molina, J. R., Sun, Y., Protopopova, M., Gera, S., Bandi, M., Bristow, C., McAfoos, T., Morlacchi, P., Ackroyd, J., Agip, A. N. A., et al. (2018). An inhibitor of oxidative phosphorylation exploits cancer vulnerability. Nature Medicine, 24(7), 1036–1046. https://doi.org/10.1038/s41591-018-0052-4CrossRefPubMed

69.

Vyas, A., Harbison, R. A., Faden, D. L., Kubik, M., Palmer, D., Zhang, Q., Osmanbeyoglu, H. U., Kiselyov, K., Méndez, E., & Duvvuri, U. (2021). Recurrent human papillomavirus–related head and neck cancer undergoes metabolic reprogramming and is driven by oxidative phosphorylation. Clinical Cancer Research, 27(22), 6250–6264. https://doi.org/10.1158/1078-0432.CCR-20-4789CrossRefPubMedPubMedCentral

70.

Yap, T. A., Rodon Ahnert, J., Piha-Paul, S. A., Fu, S., Janku, F., Karp, D. D., Naing, A., Ileana Dumbrava, E. E., Pant, S., Subbiah, V., et al. (2019). Phase I trial of IACS-010759 (IACS), a potent, selective inhibitor of complex I of the mitochondrial electron transport chain, in patients (pts) with advanced solid tumors. Journal of Clinical Oncology, 37(15_suppl), 3014–3014. https://doi.org/10.1200/JCO.2019.37.15_suppl.3014CrossRef

71.

Nouri, K., Feng, Y., & Schimmer, A. D. (2020). Mitochondrial ClpP serine protease-biological function and emerging target for cancer therapy. Cell Death & Disease, 11(10), 1–12. https://doi.org/10.1038/s41419-020-03062-zCrossRef

72.

Graves, P. R., Aponte-Collazo, L. J., Fennell, E. M. J., Graves, A. C., Hale, A. E., Dicheva, N., Herring, L. E., Gilbert, T. S. K., East, M. P., McDonald, I. M., et al. (2019). Mitochondrial protease ClpP is a target for the anticancer compounds ONC201 and related analogues. ACS Chemical Biology, 14(5), 1020–1029. https://doi.org/10.1021/acschembio.9b00222CrossRefPubMedPubMedCentral

73.

Shi, Y., Lim, S. K., Liang, Q., Iyer, S. V., Wang, H.-Y., Wang, Z., Xie, X., Sun, D., Chen, Y.-J., Tabar, V., et al. (2019). Gboxin is an oxidative phosphorylation inhibitor that targets glioblastoma. Nature, 567(7748), 341–346. https://doi.org/10.1038/s41586-019-0993-xCrossRefPubMedPubMedCentral

74.

Zhang, X., Fryknäs, M., Hernlund, E., Fayad, W., De Milito, A., Olofsson, M. H., Gogvadze, V., Dang, L., Påhlman, S., Schughart, L. A. K., et al. (2014). Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments. Nature Communications, 5(1), 1–14. https://doi.org/10.1038/ncomms4295CrossRef

75.

Sharon, D., Cathelin, S., Mirali, S., Di Trani, J. M., Yanofsky, D. J., Keon, K. A., Rubinstein, J. L., Schimmer, A. D., Ketela, T., & Chan, S. M. (2019). Inhibition of mitochondrial translation overcomes venetoclax resistance in AML through activation of the integrated stress response. Science Translational Medicine, 11(516), 2863. https://doi.org/10.1126/scitranslmed.aax2863CrossRef

76.

Kuntz, E. M., Baquero, P., Michie, A. M., Dunn, K., Tardito, S., Holyoake, T. L., Helgason, G. V., & Gottlieb, E. (2017). Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells. Nature Medicine, 23(10), 1234–1240. https://doi.org/10.1038/nm.4399CrossRefPubMedPubMedCentral

77.

Taanman, J.-W. (1999). The mitochondrial genome: structure, transcription, translation and replication. Biochimica et Biophysica Acta (BBA) - Bioenergetics, 1410(2), 103–123. https://doi.org/10.1016/S0005-2728(98)00161-3CrossRefPubMed

78.

Bonekamp, N. A., Peter, B., Hillen, H. S., Felser, A., Bergbrede, T., Choidas, A., Horn, M., Unger, A., Di Lucrezia, R., Atanassov, I., et al. (2020). Small-molecule inhibitors of human mitochondrial DNA transcription. Nature, 588(7839), 712–716. https://doi.org/10.1038/s41586-020-03048-zCrossRefPubMed

79.

Samudio, I., Harmancey, R., Fiegl, M., Kantarjian, H., Konopleva, M., Korchin, B., Kaluarachchi, K., Bornmann, W., Duvvuri, S., Taegtmeyer, H., et al. (2010). Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. The Journal of Clinical Investigation, 120(1), 142–156. https://doi.org/10.1172/JCI38942CrossRefPubMed

80.

Caro, P., Kishan, A. U., Norberg, E., Stanley, I., Chapuy, B., Ficarro, S. B., Polak, K., Tondera, D., Gounarides, J., Yin, H., et al. (2012). Metabolic signatures uncover distinct targets in molecular subsets of diffuse large B-cell lymphoma. Cancer cell, 22(4), 547–560. https://doi.org/10.1016/j.ccr.2012.08.014CrossRefPubMedPubMedCentral

81.

Menendez, J. A., & Lupu, R. (2017). Fatty acid synthase (FASN) as a therapeutic target in breast cancer. Expert Opinion on Therapeutic Targets, 21(11), 1001–1016. https://doi.org/10.1080/14728222.2017.1381087CrossRefPubMed

82.

Heuer, T. S., Ventura, R., Mordec, K., Lai, J., Fridlib, M., Buckley, D., & Kemble, G. (2017). FASN inhibition and taxane treatment combine to enhance anti-tumor efficacy in diverse xenograft tumor models through disruption of tubulin palmitoylation and microtubule organization and fasn inhibition-mediated effects on oncogenic signaling and gene expression. EBioMedicine, 16, 51–62. https://doi.org/10.1016/j.ebiom.2016.12.012CrossRefPubMed

83.

Zaytseva, Y. Y., Rychahou, P. G., Le, A.-T., Scott, T. L., Flight, R. M., Kim, J. T., Harris, J., Liu, J., Wang, C., Morris, A. J., et al. (2018). Preclinical evaluation of novel fatty acid synthase inhibitors in primary colorectal cancer cells and a patient-derived xenograft model of colorectal cancer. Oncotarget, 9(37), 24787–24800. https://doi.org/10.18632/oncotarget.25361CrossRefPubMedPubMedCentral

84.

Falchook, G., Infante, J., Arkenau, H.-T., Patel, M. R., Dean, E., Borazanci, E., Brenner, A., Cook, N., Lopez, J., Pant, S., et al. (2021). First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors. eClinicalMedicine, 34. https://doi.org/10.1016/j.eclinm.2021.100797CrossRef

85.

Feng, W. W., Wilkins, O., Bang, S., Ung, M., Li, J., An, J., del Genio, C., Canfield, K., DiRenzo, J., Wells, W., et al. (2019). CD36-mediated metabolic rewiring of breast cancer cells promotes resistance to HER2-targeted therapies. Cell Reports, 29(11), 3405–3420.e5. https://doi.org/10.1016/j.celrep.2019.11.008CrossRefPubMed

86.

Hernlund, E., Ihrlund, L. S., Khan, O., Ates, Y. O., Linder, S., Panaretakis, T., & Shoshan, M. C. (2008). Potentiation of chemotherapeutic drugs by energy metabolism inhibitors 2-deoxyglucose and etomoxir. International Journal of Cancer, 123(2), 476–483. https://doi.org/10.1002/ijc.23525CrossRefPubMed

87.

Holubarsch, C. J. F., Rohrbach, M., Karrasch, M., Boehm, E., Polonski, L., Ponikowski, P., & Rhein, S. (2007). A double-blind randomized multicentre clinical trial to evaluate the efficacy and safety of two doses of etomoxir in comparison with placebo in patients with moderate congestive heart failure: the ERGO (etomoxir for the recovery of glucose oxidation) study. Clinical Science, 113(4), 205–212. https://doi.org/10.1042/CS20060307CrossRefPubMed

88.

Zachar, Z., Marecek, J., Maturo, C., Gupta, S., Stuart, S. D., Howell, K., Schauble, A., Lem, J., Piramzadian, A., Karnik, S., et al. (2011). Non-redox-active lipoate derivates disrupt cancer cell mitochondrial metabolism and are potent anticancer agents in vivo. Journal of Molecular Medicine, 89(11), 1137. https://doi.org/10.1007/s00109-011-0785-8CrossRefPubMed

89.

Arnold, C., Demuth, P., Seiwert, N., Wittmann, S., Boengler, K., Rasenberger, B., Christmann, M., Huber, M., Brunner, T., Linnebacher, M., et al. (2022). The mitochondrial disruptor devimistat (CPI-613) synergizes with genotoxic anticancer drugs in colorectal cancer therapy in a Bim-dependent manner. Molecular Cancer Therapeutics, 21(1), 100–112. https://doi.org/10.1158/1535-7163.MCT-21-0393CrossRefPubMed

90.

Pardee, T. S., Luther, S., Buyse, M., Powell, B. L., & Cortes, J. (2019). Devimistat in combination with high dose cytarabine and mitoxantrone compared with high dose cytarabine and mitoxantrone in older patients with relapsed/refractory acute myeloid leukemia: ARMADA 2000 Phase III study. Future Oncology, 15(28), 3197–3208. https://doi.org/10.2217/fon-2019-0201CrossRefPubMed

91.

Anderson, R., Miller, L. D., Isom, S., Chou, J. W., Pladna, K. M., Schramm, N. J., Ellis, L. R., Howard, D. S., Bhave, R. R., Manuel, M., et al. (2022). Phase II trial of cytarabine and mitoxantrone with devimistat in acute myeloid leukemia. Nature Communications, 13(1), 1673. https://doi.org/10.1038/s41467-022-29039-4CrossRefPubMedPubMedCentral

92.

Tsvetkov, P., Coy, S., Petrova, B., Dreishpoon, M., Verma, A., Abdusamad, M., Rossen, J., Joesch-Cohen, L., Humeidi, R., Spangler, R. D., et al. (2022). Copper induces cell death by targeting lipoylated TCA cycle proteins. Science, 375(6586), 1254–1261. https://doi.org/10.1126/science.abf0529CrossRefPubMedPubMedCentral

93.

Tsvetkov, P., Detappe, A., Cai, K., Keys, H. R., Brune, Z., Ying, W., Thiru, P., Reidy, M., Kugener, G., Rossen, J., et al. (2019). Mitochondrial metabolism promotes adaptation to proteotoxic stress. Nature Chemical Biology, 15(7), 681–689. https://doi.org/10.1038/s41589-019-0291-9CrossRefPubMedPubMedCentral

94.

de Groot, S., Pijl, H., van der Hoeven, J. J. M., & Kroep, J. R. (2019). Effects of short-term fasting on cancer treatment. Journal of Experimental & Clinical Cancer Research : CR, 38, 209. https://doi.org/10.1186/s13046-019-1189-9CrossRefPubMedCentral

95.

Caffa, I., Spagnolo, V., Vernieri, C., Valdemarin, F., Becherini, P., Wei, M., Brandhorst, S., Zucal, C., Driehuis, E., Ferrando, L., et al. (2020). Fasting-mimicking diet and hormone therapy induce breast cancer regression. Nature, 583(7817), 620–624. https://doi.org/10.1038/s41586-020-2502-7CrossRefPubMedPubMedCentral

96.

Thandapani, P., Kloetgen, A., Witkowski, M. T., Glytsou, C., Lee, A. K., Wang, E., Wang, J., LeBoeuf, S. E., Avrampou, K., Papagiannakopoulos, T., et al. (2022). Valine tRNA levels and availability regulate complex I assembly in leukaemia. Nature, 601(7893), 428–433. https://doi.org/10.1038/s41586-021-04244-1CrossRefPubMed

97.

Rose, D. P. (1997). Effects of dietary fatty acids on breast and prostate cancers: evidence from in vitro experiments and animal studies. The American Journal of Clinical Nutrition, 66(6), 1513S–1522S. https://doi.org/10.1093/ajcn/66.6.1513SCrossRefPubMed

98.

Donnelly, C., Olsen, A. M., Lewis, L. D., Eisenberg, B. L., Eastman, A., & Kinlaw, W. B. (2009). Conjugated Linoleic Acid (CLA) inhibits expression of the spot 14 (THRSP) and fatty acid synthase genes and impairs the growth of human breast cancer and liposarcoma cells. Nutrition and Cancer, 61(1), 114–122. https://doi.org/10.1080/01635580802348666CrossRefPubMedPubMedCentral

99.

McGowan, M. M., Eisenberg, B. L., Lewis, L. D., Froehlich, H. M., Wells, W. A., Eastman, A., Kuemmerle, N. B., Rosenkrantz, K. M., Barth, R. J., Schwartz, G. N., et al. (2013). A proof of principle clinical trial to determine whether conjugated linoleic acid modulates the lipogenic pathway in human breast cancer tissue. Breast Cancer Research and Treatment, 138(1), 175–183. https://doi.org/10.1007/s10549-013-2446-9CrossRefPubMedPubMedCentral

100.

Mayer, E. L., Dueck, A. C., Martin, M., Rubovszky, G., Burstein, H. J., Bellet-Ezquerra, M., Miller, K. D., Zdenkowski, N., Winer, E. P., Pfeiler, G., et al. (2021). Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): Interim analysis of a multicentre, open-label, randomised, phase 3 study. The Lancet Oncology, 22(2), 212–222. https://doi.org/10.1016/S1470-2045(20)30642-2CrossRefPubMed

101.

Vansteenkiste, J. F., Cho, B. C., Vanakesa, T., De Pas, T., Zielinski, M., Kim, M. S., Jassem, J., Yoshimura, M., Dahabreh, J., Nakayama, H., et al. (2016). Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): A randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. Oncology, 17(6), 822–835. https://doi.org/10.1016/S1470-2045(16)00099-1CrossRefPubMed

102.

Alberts, S. R., Sargent, D. J., Nair, S., Mahoney, M. R., Mooney, M., Thibodeau, S. N., Smyrk, T. C., Sinicrope, F. A., Chan, E., Gill, S., et al. (2012). Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: A randomized trial. JAMA, 307(13), 1383–1393. https://doi.org/10.1001/jama.2012.385CrossRefPubMedPubMedCentral

103.

Nielsen, T. O., Jensen, M.-B., Burugu, S., Gao, D., Jørgensen, C. L. T., Balslev, E., & Ejlertsen, B. (2017). High-risk premenopausal luminal a breast cancer patients derive no benefit from adjuvant cyclophosphamide-based chemotherapy: Results from the DBCG77B clinical trial. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 23(4), 946–953. https://doi.org/10.1158/1078-0432.CCR-16-1278CrossRefPubMed

104.

Haas, N. B., Manola, J., Uzzo, R. G., Flaherty, K. T., Wood, C. G., Kane, C., Jewett, M., Dutcher, J. P., Atkins, M. B., Pins, M., et al. (2016). Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): A double-blind, placebo-controlled, randomised, phase 3 trial. Lancet (London, England), 387(10032), 2008–2016. https://doi.org/10.1016/S0140-6736(16)00559-6CrossRefPubMed

105.

de Gramont, A., Van Cutsem, E., Schmoll, H.-J., Tabernero, J., Clarke, S., Moore, M. J., Cunningham, D., Cartwright, T. H., Hecht, J. R., Rivera, F., et al. (2012). Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): A phase 3 randomised controlled trial. The Lancet Oncology, 13(12), 1225–1233. https://doi.org/10.1016/S1470-2045(12)70509-0CrossRefPubMed

106.

Allegra, C. J., Yothers, G., O’Connell, M. J., Sharif, S., Petrelli, N. J., Colangelo, L. H., Atkins, J. N., Seay, T. E., Fehrenbacher, L., Goldberg, R. M., et al. (2011). Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: Results of NSABP protocol C-08. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 29(1), 11–16. https://doi.org/10.1200/JCO.2010.30.0855CrossRefPubMed

Titel: The role of cancer cell bioenergetics in dormancy and drug resistance
verfasst von: Steven Tau
Todd W. Miller
Publikationsdatum: 25.01.2023
Verlag: Springer US
Erschienen in: Cancer and Metastasis Reviews / Ausgabe 1/2023
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-023-10081-7

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

The role of cancer cell bioenergetics in dormancy and drug resistance

Abstract

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2023

Autophagy, molecular chaperones, and unfolded protein response as promoters of tumor recurrence

The genomic regulation of metastatic dormancy

Dormancy in cancer metastasis: keys to moving forward

KISS1 metastasis suppressor in tumor dormancy: a potential therapeutic target for metastatic cancers?

Preface

The genetic profile and molecular subtypes of human pseudomyxoma peritonei and appendiceal mucinous neoplasms: a systematic review

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie